10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

NB3 (Neurocrine) Stock Analysis
Buy, Hold or Sell?

Let's analyze Neurocrine together

I guess you are interested in Neurocrine Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Neurocrine’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Neurocrine’s Price Targets

I'm going to help you getting a better view of Neurocrine Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Neurocrine Biosciences Inc

I send you an email if I find something interesting about Neurocrine Biosciences Inc.

1. Quick Overview

1.1. Quick analysis of Neurocrine (30 sec.)










1.2. What can you expect buying and holding a share of Neurocrine? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€23.31
Expected worth in 1 year
€25.28
How sure are you?
77.1%

+ What do you gain per year?

Total Gains per Share
€1.97
Return On Investment
1.4%

For what price can you sell your share?

Current Price per Share
€136.05
Expected price per share
€116.40 - €147.45
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Neurocrine (5 min.)




Live pricePrice per Share (EOD)
€136.05
Intrinsic Value Per Share
€12.13 - €12.97
Total Value Per Share
€35.44 - €36.28

2.2. Growth of Neurocrine (5 min.)




Is Neurocrine growing?

Current yearPrevious yearGrowGrow %
How rich?$2.6b$2.2b$352.3m13.4%

How much money is Neurocrine making?

Current yearPrevious yearGrowGrow %
Making money$87m$84.8m$2.2m2.6%
Net Profit Margin13.6%16.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Neurocrine (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Neurocrine?

Welcome investor! Neurocrine's management wants to use your money to grow the business. In return you get a share of Neurocrine.

First you should know what it really means to hold a share of Neurocrine. And how you can make/lose money.

Speculation

The Price per Share of Neurocrine is €136.05. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Neurocrine.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Neurocrine, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €23.31. Based on the TTM, the Book Value Change Per Share is €0.49 per quarter. Based on the YOY, the Book Value Change Per Share is €1.33 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Neurocrine.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps1.080.8%0.870.6%0.850.6%0.720.5%0.620.5%0.350.3%
Usd Book Value Change Per Share1.601.2%0.570.4%1.551.1%1.070.8%0.940.7%0.780.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.601.2%0.570.4%1.551.1%1.070.8%0.940.7%0.780.6%
Usd Price Per Share124.07-129.49-140.84-128.27-114.88-101.09-
Price to Earnings Ratio28.61-116.38-51.25-61.88-32.98-19.59-
Price-to-Total Gains Ratio77.58--74.82-99.17--9.61-56.96-68.32-
Price to Book Ratio4.57-4.91-6.17-5.94-6.68-12.03-
Price-to-Total Gains Ratio77.58--74.82-99.17--9.61-56.96-68.32-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share158.566275
Number of shares6
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.570.94
Usd Total Gains Per Share0.570.94
Gains per Quarter (6 shares)3.455.64
Gains per Year (6 shares)13.7822.54
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1014402313
20281804536
30413206859
40554609082
5069600113105
6083740135128
7096880158151
801101020180174
901241160203197
1001381300225220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%11.01.00.091.7%16.04.00.080.0%24.011.00.068.6%24.011.00.068.6%
Book Value Change Per Share2.02.00.050.0%9.03.00.075.0%16.04.00.080.0%27.08.00.077.1%27.08.00.077.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.035.00.0%0.00.035.00.0%
Total Gains per Share2.02.00.050.0%9.03.00.075.0%16.04.00.080.0%27.08.00.077.1%27.08.00.077.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Neurocrine Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.3720.493+178%1.327+3%0.916+50%0.806+70%0.666+106%
Book Value Per Share--23.31122.665+3%19.582+19%18.978+23%15.691+49%10.605+120%
Current Ratio--3.2013.525-9%2.888+11%3.103+3%3.575-10%5.705-44%
Debt To Asset Ratio--0.3070.289+7%0.291+6%0.288+7%0.314-2%0.383-20%
Debt To Equity Ratio--0.4440.409+9%0.413+7%0.406+9%0.465-5%0.693-36%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--9532013189.50010157047264.625-6%11280891801.425-16%10200790821.950-7%9118499627.255+5%8218437744.557+16%
Eps--0.9300.747+24%0.730+27%0.620+50%0.535+74%0.301+209%
Ev To Sales Ratio--4.0394.731-15%6.203-35%5.789-30%6.518-38%15.114-73%
Free Cash Flow Per Share--0.7741.136-32%1.064-27%0.936-17%0.726+7%0.720+8%
Free Cash Flow To Equity Per Share--0.7460.304+145%0.708+5%0.574+30%0.327+128%0.364+105%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--12.967----------
Intrinsic Value_10Y_min--12.128----------
Intrinsic Value_1Y_max--3.394----------
Intrinsic Value_1Y_min--3.335----------
Intrinsic Value_3Y_max--8.602----------
Intrinsic Value_3Y_min--8.245----------
Intrinsic Value_5Y_max--11.885----------
Intrinsic Value_5Y_min--11.169----------
Market Cap13493644435.500+22%10557871739.50011077917279.625-5%12084845691.425-13%10968454232.783-4%9807794195.255+8%8784632473.785+20%
Net Profit Margin--0.1560.136+15%0.162-3%0.134+16%0.1560%-0.180+215%
Operating Margin----0%-0%0.046-100%0.100-100%-0.1780%
Operating Ratio--0.8050.820-2%0.760+6%0.8070%0.817-1%1.095-27%
Pb Ratio5.836+22%4.5674.908-7%6.175-26%5.941-23%6.678-32%12.026-62%
Pe Ratio36.570+22%28.613116.379-75%51.253-44%61.882-54%32.982-13%19.586+46%
Price Per Share136.050+22%106.450111.100-4%120.838-12%110.056-3%98.567+8%86.737+23%
Price To Free Cash Flow Ratio43.925+22%34.36831.448+9%36.865-7%26.738+29%-8.738+125%-2.348+107%
Price To Total Gains Ratio99.149+22%77.577-74.823+196%99.167-22%-9.606+112%56.955+36%68.323+14%
Quick Ratio--2.3932.646-10%2.208+8%2.373+1%2.534-6%3.789-37%
Return On Assets--0.0280.024+17%0.027+4%0.023+21%0.024+15%0.003+781%
Return On Equity--0.0400.033+22%0.038+5%0.032+24%0.035+15%0.006+538%
Total Gains Per Share--1.3720.493+178%1.327+3%0.916+50%0.806+70%0.666+106%
Usd Book Value--2694611326.3652634954433.808+2%2282613725.543+18%2205079767.529+22%1820595345.487+48%1238449543.454+118%
Usd Book Value Change Per Share--1.5990.574+178%1.546+3%1.068+50%0.939+70%0.776+106%
Usd Book Value Per Share--27.16826.416+3%22.823+19%22.119+23%18.288+49%12.361+120%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--11109561372.36211838038586.920-6%13147879394.561-16%11889021702.983-7%10627611315.566+5%9578589191.281+16%
Usd Eps--1.0840.871+24%0.851+27%0.722+50%0.623+74%0.351+209%
Usd Free Cash Flow--89510341.725132190272.821-32%123664287.758-28%108687557.396-18%84254734.510+6%52463204.280+71%
Usd Free Cash Flow Per Share--0.9021.324-32%1.240-27%1.091-17%0.846+7%0.839+8%
Usd Free Cash Flow To Equity Per Share--0.8690.354+145%0.825+5%0.669+30%0.381+128%0.425+105%
Usd Market Cap15726842589.575+22%12305199512.38712911312589.403-5%14084887653.356-13%12783733408.309-4%11430984134.570+8%10238489148.197+20%
Usd Price Per Share158.566+22%124.067129.487-4%140.836-12%128.270-3%114.880+8%101.092+23%
Usd Profit--107512421.62587085061.516+23%84809798.640+27%71999985.304+49%62047168.722+73%35110399.395+206%
Usd Revenue--687579440.625627547504.736+10%529936227.056+30%525260686.860+31%431604866.180+59%302079272.656+128%
Usd Total Gains Per Share--1.5990.574+178%1.546+3%1.068+50%0.939+70%0.776+106%
 EOD+4 -4MRQTTM+21 -14YOY+21 -143Y+23 -135Y+29 -710Y+29 -6

3.3 Fundamental Score

Let's check the fundamental score of Neurocrine Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1536.570
Price to Book Ratio (EOD)Between0-15.836
Net Profit Margin (MRQ)Greater than00.156
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.393
Current Ratio (MRQ)Greater than13.201
Debt to Asset Ratio (MRQ)Less than10.307
Debt to Equity Ratio (MRQ)Less than10.444
Return on Equity (MRQ)Greater than0.150.040
Return on Assets (MRQ)Greater than0.050.028
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Neurocrine Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5080.915
Ma 20Greater thanMa 50119.670
Ma 50Greater thanMa 100119.427
Ma 100Greater thanMa 200114.915
OpenGreater thanClose127.200
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2025-10-13 18:29:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is fair priced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Neurocrine earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Neurocrine to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 15.6%Β means thatΒ €0.16 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Neurocrine Biosciences Inc:

  • The MRQ is 15.6%. The company is making a huge profit. +2
  • The TTM is 13.6%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ15.6%TTM13.6%+2.1%
TTM13.6%YOY16.2%-2.6%
TTM13.6%5Y15.6%-2.1%
5Y15.6%10Y-18.0%+33.6%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Neurocrine is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Neurocrine to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 2.8% Return on Assets means thatΒ Neurocrine generatedΒ €0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Neurocrine Biosciences Inc:

  • The MRQ is 2.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.4%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.8%TTM2.4%+0.4%
TTM2.4%YOY2.7%-0.3%
TTM2.4%5Y2.4%-0.1%
5Y2.4%10Y0.3%+2.1%
4.3.1.3. Return on Equity

Shows how efficient Neurocrine is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Neurocrine to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 4.0% Return on Equity means Neurocrine generated €0.04Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Neurocrine Biosciences Inc:

  • The MRQ is 4.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.3%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ4.0%TTM3.3%+0.7%
TTM3.3%YOY3.8%-0.5%
TTM3.3%5Y3.5%-0.2%
5Y3.5%10Y0.6%+2.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Neurocrine Biosciences Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Neurocrine is operatingΒ .

  • Measures how much profit Neurocrine makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Neurocrine to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Neurocrine Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y10.0%-10.0%
5Y10.0%10Y-17.8%+27.8%
4.3.2.2. Operating Ratio

Measures how efficient Neurocrine is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.80 means that the operating costs are €0.80 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Neurocrine Biosciences Inc:

  • The MRQ is 0.805. The company is less efficient in keeping operating costs low.
  • The TTM is 0.820. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.805TTM0.820-0.015
TTM0.820YOY0.760+0.060
TTM0.8205Y0.817+0.003
5Y0.81710Y1.095-0.279
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Neurocrine Biosciences Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Neurocrine is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.20Β means the company has €3.20 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Neurocrine Biosciences Inc:

  • The MRQ is 3.201. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.525. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.201TTM3.525-0.323
TTM3.525YOY2.888+0.636
TTM3.5255Y3.575-0.051
5Y3.57510Y5.705-2.130
4.4.3.2. Quick Ratio

Measures if Neurocrine is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Neurocrine to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 2.39Β means the company can pay off €2.39 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Neurocrine Biosciences Inc:

  • The MRQ is 2.393. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.646. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.393TTM2.646-0.253
TTM2.646YOY2.208+0.438
TTM2.6465Y2.534+0.112
5Y2.53410Y3.789-1.255
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Neurocrine Biosciences Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of NeurocrineΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Neurocrine to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.31Β means that Neurocrine assets areΒ financed with 30.7% credit (debt) and the remaining percentage (100% - 30.7%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Neurocrine Biosciences Inc:

  • The MRQ is 0.307. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.289. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.307TTM0.289+0.019
TTM0.289YOY0.291-0.003
TTM0.2895Y0.314-0.025
5Y0.31410Y0.383-0.070
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Neurocrine is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Neurocrine to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 44.4% means that company has €0.44 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Neurocrine Biosciences Inc:

  • The MRQ is 0.444. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.409. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.444TTM0.409+0.035
TTM0.409YOY0.413-0.004
TTM0.4095Y0.465-0.056
5Y0.46510Y0.693-0.228
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Neurocrine generates.

  • Above 15 is considered overpriced butΒ always compareΒ Neurocrine to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 28.61 means the investor is paying €28.61Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Neurocrine Biosciences Inc:

  • The EOD is 36.570. Based on the earnings, the company is overpriced. -1
  • The MRQ is 28.613. Based on the earnings, the company is overpriced. -1
  • The TTM is 116.379. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD36.570MRQ28.613+7.956
MRQ28.613TTM116.379-87.766
TTM116.379YOY51.253+65.126
TTM116.3795Y32.982+83.397
5Y32.98210Y19.586+13.395
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Neurocrine Biosciences Inc:

  • The EOD is 43.925. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 34.368. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 31.448. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD43.925MRQ34.368+9.557
MRQ34.368TTM31.448+2.920
TTM31.448YOY36.865-5.418
TTM31.4485Y-8.738+40.186
5Y-8.73810Y-2.348-6.390
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Neurocrine is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 4.57 means the investor is paying €4.57Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Neurocrine Biosciences Inc:

  • The EOD is 5.836. Based on the equity, the company is overpriced. -1
  • The MRQ is 4.567. Based on the equity, the company is fair priced.
  • The TTM is 4.908. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD5.836MRQ4.567+1.270
MRQ4.567TTM4.908-0.341
TTM4.908YOY6.175-1.266
TTM4.9085Y6.678-1.770
5Y6.67810Y12.026-5.347
4.6.2. Total Gains per Share

2.4. Latest News of Neurocrine Biosciences Inc

Does Neurocrine Biosciences Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Neurocrine Biosciences Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-10-29
00:30
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 EarningsRead
2025-10-28
22:10
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top EstimatesRead
2025-10-28
21:45
Neurocrine Shares Rise, But Pull Back From Steep Gains, On Strong Ingrezza QuarterRead
2025-10-25
14:14
Examining Neurocrine Biosciences Valuation After 24% Stock Surge and Pipeline Progress in 2025Read
2025-10-06
22:05
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry FranchiseRead
2025-10-06
21:52
Sector Update: Health Care Stocks Retreat Late AfternoonRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets3,889,800
Total Liabilities1,195,500
Total Stockholder Equity2,694,300
 As reported
Total Liabilities 1,195,500
Total Stockholder Equity+ 2,694,300
Total Assets = 3,889,800

Assets

Total Assets3,889,800
Total Current Assets1,748,900
Long-term Assets2,140,900
Total Current Assets
Cash And Cash Equivalents 264,000
Short-term Investments 711,600
Net Receivables 595,700
Inventory 56,900
Other Current Assets 120,700
Total Current Assets  (as reported)1,748,900
Total Current Assets  (calculated)1,748,900
+/-0
Long-term Assets
Property Plant Equipment 584,000
Long Term Investments 961,300
Intangible Assets 37,200
Long-term Assets Other 21,600
Long-term Assets  (as reported)2,140,900
Long-term Assets  (calculated)1,604,100
+/- 536,800

Liabilities & Shareholders' Equity

Total Current Liabilities546,300
Long-term Liabilities649,200
Total Stockholder Equity2,694,300
Total Current Liabilities
Accounts payable 104,600
Other Current Liabilities 56,800
Total Current Liabilities  (as reported)546,300
Total Current Liabilities  (calculated)161,400
+/- 384,900
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt439,100
Long-term Liabilities Other 27,100
Long-term Liabilities  (as reported)649,200
Long-term Liabilities  (calculated)466,200
+/- 183,000
Total Stockholder Equity
Retained Earnings 84,500
Total Stockholder Equity (as reported)2,694,300
Total Stockholder Equity (calculated)84,500
+/- 2,609,800
Other
Capital Stock100
Common Stock Shares Outstanding 98,966
Net Invested Capital 2,694,300
Net Working Capital 1,202,600
Property Plant and Equipment Gross 584,000



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
365,086
289,364
754,086
772,496
817,591
806,360
841,317
933,746
993,151
957,723
1,066,861
1,179,935
1,306,040
1,361,900
1,515,600
1,502,600
1,734,700
1,846,400
1,956,400
2,017,300
2,072,500
2,144,500
2,005,700
2,143,400
2,368,700
2,359,800
2,613,100
2,848,200
3,251,400
3,472,400
3,305,000
3,535,000
3,718,700
3,687,700
3,889,800
3,889,8003,687,7003,718,7003,535,0003,305,0003,472,4003,251,4002,848,2002,613,1002,359,8002,368,7002,143,4002,005,7002,144,5002,072,5002,017,3001,956,4001,846,4001,734,7001,502,6001,515,6001,361,9001,306,0401,179,9351,066,861957,723993,151933,746841,317806,360817,591772,496754,086289,364365,086
   > Total Current Assets 
310,442
239,451
536,751
548,485
554,919
513,716
567,677
714,394
737,777
633,192
748,808
819,232
831,034
968,200
1,146,200
1,156,900
1,016,200
1,085,400
1,110,100
1,005,700
972,800
1,018,200
1,019,300
1,205,500
1,453,500
1,432,800
1,496,600
1,649,900
1,607,000
1,799,000
1,669,800
1,876,600
1,724,700
1,637,900
1,748,900
1,748,9001,637,9001,724,7001,876,6001,669,8001,799,0001,607,0001,649,9001,496,6001,432,8001,453,5001,205,5001,019,3001,018,200972,8001,005,7001,110,1001,085,4001,016,2001,156,9001,146,200968,200831,034819,232748,808633,192737,777714,394567,677513,716554,919548,485536,751239,451310,442
       Cash And Cash Equivalents 
83,267
64,087
309,498
267,818
254,712
175,311
166,422
195,734
141,714
72,778
140,985
166,637
112,279
187,000
415,100
425,300
801,000
352,600
368,000
311,100
340,800
270,200
163,300
212,200
262,900
103,800
160,200
293,700
251,100
396,300
139,700
349,100
233,000
194,100
264,000
264,000194,100233,000349,100139,700396,300251,100293,700160,200103,800262,900212,200163,300270,200340,800311,100368,000352,600801,000425,300415,100187,000112,279166,637140,98572,778141,714195,734166,422175,311254,712267,818309,49864,08783,267
       Short-term Investments 
224,083
171,493
215,522
243,200
261,217
285,168
342,318
439,609
509,199
451,290
478,993
503,525
558,245
584,700
533,200
519,400
613,900
521,100
516,900
454,800
370,500
394,700
485,000
587,200
726,400
790,800
816,500
801,400
780,500
814,300
899,200
878,900
843,100
749,400
711,600
711,600749,400843,100878,900899,200814,300780,500801,400816,500790,800726,400587,200485,000394,700370,500454,800516,900521,100613,900519,400533,200584,700558,245503,525478,993451,290509,199439,609342,318285,168261,217243,200215,522171,493224,083
       Net Receivables 
0
0
6,074
29,818
31,127
44,624
42,646
54,097
56,240
71,964
95,357
115,318
126,575
148,600
148,400
156,900
157,100
147,800
158,500
163,800
185,500
263,500
279,000
301,200
350,000
391,600
387,600
417,800
439,300
450,700
468,200
481,100
479,100
516,000
595,700
595,700516,000479,100481,100468,200450,700439,300417,800387,600391,600350,000301,200279,000263,500185,500163,800158,500147,800157,100156,900148,400148,600126,575115,31895,35771,96456,24054,09742,64644,62431,12729,8186,07400
       Other Current Assets 
3,092
3,871
5,529
7,407
7,863
8,613
16,291
18,900
19,760
24,150
21,455
22,954
16,647
26,700
27,500
34,700
30,100
33,800
38,400
50,500
45,500
60,800
62,700
67,900
79,100
113,200
519,900
100,200
97,800
100,500
120,200
121,700
112,100
119,300
120,700
120,700119,300112,100121,700120,200100,50097,800100,200519,900113,20079,10067,90062,70060,80045,50050,50038,40033,80030,10034,70027,50026,70016,64722,95421,45524,15019,76018,90016,2918,6137,8637,4075,5293,8713,092
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
324,531
318,053
360,703
475,006
393,700
369,400
345,700
718,500
761,000
846,300
1,011,600
1,099,700
1,126,300
986,400
937,900
915,200
927,000
1,116,500
1,198,300
1,644,400
1,673,400
1,635,200
1,658,400
1,994,000
2,049,800
2,140,900
2,140,9002,049,8001,994,0001,658,4001,635,2001,673,4001,644,4001,198,3001,116,500927,000915,200937,900986,4001,126,3001,099,7001,011,600846,300761,000718,500345,700369,400393,700475,006360,703318,053324,531000000000
       Property Plant Equipment 
6,271
7,144
6,954
9,140
10,811
11,825
18,775
28,618
33,869
85,965
88,708
102,289
116,278
115,200
116,700
114,000
127,400
142,300
150,300
149,000
155,800
158,600
159,000
150,500
145,600
147,200
149,100
149,600
347,300
346,100
343,000
337,300
592,000
589,200
584,000
584,000589,200592,000337,300343,000346,100347,300149,600149,100147,200145,600150,500159,000158,600155,800149,000150,300142,300127,400114,000116,700115,200116,278102,28988,70885,96533,86928,61818,77511,82510,8119,1406,9547,1446,271
       Long Term Investments 
43,490
37,686
205,768
210,258
247,361
276,319
249,388
185,257
216,028
233,089
223,868
253,708
355,522
275,300
245,900
225,100
265,300
288,500
376,700
549,000
624,400
632,300
489,000
457,500
401,500
380,300
515,600
587,500
849,400
863,900
781,400
770,600
864,300
909,500
961,300
961,300909,500864,300770,600781,400863,900849,400587,500515,600380,300401,500457,500489,000632,300624,400549,000376,700288,500265,300225,100245,900275,300355,522253,708223,868233,089216,028185,257249,388276,319247,361210,258205,76837,68643,490
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,200
37,200
36,900
34,900
35,500
34,300
33,500
34,500
36,500
36,400
37,200
37,20036,40036,50034,50033,50034,30035,50034,90036,90037,20037,200000000000000000000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
5,477
5,477
4,706
3,206
3,200
6,800
6,600
6,400
4,600
3,200
3,200
4,400
10,100
10,000
10,500
25,000
24,900
35,900
43,100
49,600
50,900
57,800
61,600
15,500
15,300
21,600
21,60015,30015,50061,60057,80050,90049,60043,10035,90024,90025,00010,50010,00010,1004,4003,2003,2004,6006,4006,6006,8003,2003,2064,7065,4775,477000000000
> Total Liabilities 
50,209
42,223
408,848
424,984
445,453
441,873
463,881
486,233
512,386
548,448
583,155
605,420
669,117
661,600
684,400
698,300
608,500
640,800
677,200
671,300
698,500
753,400
582,300
598,800
660,900
675,300
760,100
846,100
1,019,400
1,086,300
795,800
816,100
1,129,000
1,152,000
1,195,500
1,195,5001,152,0001,129,000816,100795,8001,086,3001,019,400846,100760,100675,300660,900598,800582,300753,400698,500671,300677,200640,800608,500698,300684,400661,600669,117605,420583,155548,448512,386486,233463,881441,873445,453424,984408,84842,22350,209
   > Total Current Liabilities 
30,414
23,563
27,721
38,141
54,426
46,466
61,762
456,400
88,233
72,003
100,589
115,652
565,287
140,300
573,000
611,000
186,500
190,000
212,900
225,900
245,800
253,500
285,700
485,100
537,700
374,100
582,500
691,600
654,800
712,900
398,500
429,700
507,700
522,900
546,300
546,300522,900507,700429,700398,500712,900654,800691,600582,500374,100537,700485,100285,700253,500245,800225,900212,900190,000186,500611,000573,000140,300565,287115,652100,58972,00388,233456,40061,76246,46654,42638,14127,72123,56330,414
       Short-term Debt 
0
0
360,681
365,110
369,618
374,209
378,885
383,647
88,233
3,267
0
0
408,807
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000408,807003,26788,233383,647378,885374,209369,618365,110360,68100
       Short Long Term Debt 
0
0
360,681
365,110
369,618
374,209
378,885
383,647
88,233
3,267
0
0
408,807
0
419,500
425,000
0
0
0
0
0
0
0
169,200
169,400
0
169,700
169,900
170,100
259,000
0
0
0
0
0
00000259,000170,100169,900169,7000169,400169,2000000000425,000419,5000408,807003,26788,233383,647378,885374,209369,618365,110360,68100
       Accounts payable 
26,182
19,255
26,809
37,289
5,648
45,650
61,031
72,022
13,801
68,280
95,027
102,357
46,214
125,900
137,100
170,500
39,400
171,900
190,900
205,900
51,500
235,900
265,700
297,800
76,300
355,700
0
93,800
133,300
87,300
107,200
95,700
110,000
110,000
104,600
104,600110,000110,00095,700107,20087,300133,30093,8000355,70076,300297,800265,700235,90051,500205,900190,900171,90039,400170,500137,100125,90046,214102,35795,02768,28013,80172,02261,03145,6505,64837,28926,80919,25526,182
       Other Current Liabilities 
4,232
4,308
912
852
906
816
731
731
1,856
3,723
5,562
13,295
37,547
5,600
7,200
5,800
42,100
5,900
7,000
4,500
66,200
700
2,900
800
135,200
800
21,200
800
35,900
36,700
39,800
37,000
46,000
47,700
56,800
56,80047,70046,00037,00039,80036,70035,90080021,200800135,2008002,90070066,2004,5007,0005,90042,1005,8007,2005,60037,54713,2955,5623,7231,8567317318169068529124,3084,232
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
476,445
482,566
489,768
103,830
521,300
111,400
87,300
422,000
450,800
464,300
445,400
452,700
499,900
296,600
113,700
123,200
301,200
177,600
154,500
364,600
373,400
397,300
386,400
621,300
629,100
649,200
649,200629,100621,300386,400397,300373,400364,600154,500177,600301,200123,200113,700296,600499,900452,700445,400464,300450,800422,00087,300111,400521,300103,830489,768482,566476,445000000000
       Capital Lease Obligations Min Short Term Debt
0
0
-360,681
-365,110
-369,618
-374,209
-378,885
-383,647
-88,233
63,880
66,185
74,482
-322,051
85,600
84,300
83,000
94,400
107,500
109,000
106,400
105,300
102,500
99,600
96,600
93,500
90,400
89,100
103,700
258,300
252,900
256,200
251,400
455,100
447,500
439,100
439,100447,500455,100251,400256,200252,900258,300103,70089,10090,40093,50096,60099,600102,500105,300106,400109,000107,50094,40083,00084,30085,600-322,05174,48266,18563,880-88,233-383,647-378,885-374,209-369,618-365,110-360,68100
       Other Liabilities 
730
657
20,446
21,733
21,409
21,198
23,234
29,833
35,657
15,863
17,915
11,697
17,074
21,600
27,100
4,300
9,700
21,300
29,000
8,300
12,300
19,700
28,000
17,100
29,700
41,300
0
0
0
0
0
0
0
0
0
00000000041,30029,70017,10028,00019,70012,3008,30029,00021,3009,7004,30027,10021,60017,07411,69717,91515,86335,65729,83323,23421,19821,40921,73320,446657730
> Total Stockholder Equity
314,877
247,141
345,238
347,512
372,138
364,487
377,436
447,513
480,765
409,275
483,706
574,515
636,923
700,300
831,200
804,300
1,126,200
1,205,600
1,279,200
1,346,000
1,374,000
1,391,100
1,423,400
1,544,600
1,707,800
1,684,500
1,853,000
2,002,100
2,232,000
2,386,100
2,509,200
2,718,900
2,589,700
2,535,700
2,694,300
2,694,3002,535,7002,589,7002,718,9002,509,2002,386,1002,232,0002,002,1001,853,0001,684,5001,707,8001,544,6001,423,4001,391,1001,374,0001,346,0001,279,2001,205,6001,126,200804,300831,200700,300636,923574,515483,706409,275480,765447,513377,436364,487372,138347,512345,238247,141314,877
   Common Stock
87
88
88
88
89
90
90
91
91
91
92
92
92
100
100
100
100
100
100
100
100
100
100
100
100
100
100
0
0
0
0
0
0
0
0
0000000010010010010010010010010010010010010010010092929291919190908988888887
   Retained Earnings Total Equity00000000000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000
   Other Stockholders Equity 
-318
-235
-713
-534
-1,850
-3,697
-2,809
-2,056
-1,932
-233
645
1,606
1,413
-1,400
4,600
3,200
1,800
1,000
700
400
-1,700
-9,300
-12,200
-14,000
-7,900
-2,700
-1,100
0
0
0
0
0
0
0
0
00000000-1,100-2,700-7,900-14,000-12,200-9,300-1,7004007001,0001,8003,2004,600-1,4001,4131,606645-233-1,932-2,056-2,809-3,697-1,850-534-713-235-318



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue2,355,300
Cost of Revenue-34,000
Gross Profit2,321,3002,321,300
 
Operating Income (+$)
Gross Profit2,321,300
Operating Expense-1,772,300
Operating Income583,000549,000
 
Operating Expense (+$)
Research Development731,100
Selling General Administrative1,007,200
Selling And Marketing Expenses-
Operating Expense1,772,3001,738,300
 
Net Interest Income (+$)
Interest Income91,000
Interest Expense-126,600
Other Finance Cost-0
Net Interest Income-35,600
 
Pretax Income (+$)
Operating Income583,000
Net Interest Income-35,600
Other Non-Operating Income Expenses-
Income Before Tax (EBT)486,000644,400
EBIT - interestExpense = -126,600
341,300
467,900
Interest Expense126,600
Earnings Before Interest and Taxes (EBIT)-612,600
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax486,000
Tax Provision-144,700
Net Income From Continuing Ops341,300341,300
Net Income341,300
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-61,40035,600
 

Technical Analysis of Neurocrine
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Neurocrine. The general trend of Neurocrine is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Neurocrine's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Neurocrine Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Neurocrine Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 130.75 < 147.45.

The bearish price targets are: 124.20 > 118.75 > 116.40.

Know someone who trades $NB3? Share this with them.πŸ‘‡

Neurocrine Biosciences Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Neurocrine Biosciences Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Neurocrine Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Neurocrine Biosciences Inc. The current macd is 2.28676.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neurocrine price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Neurocrine. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Neurocrine price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Neurocrine Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartNeurocrine Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Neurocrine Biosciences Inc. The current adx is 15.98.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Neurocrine shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Neurocrine Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Neurocrine Biosciences Inc. The current sar is 117.64.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Neurocrine Biosciences Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Neurocrine Biosciences Inc. The current rsi is 80.92. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Neurocrine Biosciences Inc Daily Relative Strength Index (RSI) ChartNeurocrine Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Neurocrine Biosciences Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Neurocrine price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Neurocrine Biosciences Inc Daily Stochastic Oscillator ChartNeurocrine Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Neurocrine Biosciences Inc. The current cci is 310.42.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Neurocrine Biosciences Inc Daily Commodity Channel Index (CCI) ChartNeurocrine Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Neurocrine Biosciences Inc. The current cmo is 78.20.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Neurocrine Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartNeurocrine Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Neurocrine Biosciences Inc. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Neurocrine Biosciences Inc Daily Williams %R ChartNeurocrine Biosciences Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Neurocrine Biosciences Inc. The current atr is 1.96374024.

Neurocrine Biosciences Inc Daily Average True Range (ATR) ChartNeurocrine Biosciences Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Neurocrine Biosciences Inc. The current obv is 3,194.

Neurocrine Biosciences Inc Daily On-Balance Volume (OBV) ChartNeurocrine Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Neurocrine Biosciences Inc. The current mfi is 65.07.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Neurocrine Biosciences Inc Daily Money Flow Index (MFI) ChartNeurocrine Biosciences Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Neurocrine Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-06-13 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-16 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-17 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-19 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-27 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-30 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-07-02 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-09 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-10 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-23 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-24 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-29 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-30 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-31 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-01 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-05 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-08 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-13 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-14 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-18 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-08-20 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-22 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-01 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-04 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-05 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-08 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-10 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-15 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-16 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-22 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-26 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-30 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-10-01 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-02 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-07 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-09 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-13 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-20 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-21 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-22 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-23 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-10-27 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-28 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Neurocrine Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Neurocrine Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5080.915
Ma 20Greater thanMa 50119.670
Ma 50Greater thanMa 100119.427
Ma 100Greater thanMa 200114.915
OpenGreater thanClose127.200
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Neurocrine with someone you think should read this too:
  • Are you bullish or bearish on Neurocrine? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Neurocrine? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Neurocrine Biosciences Inc

I send you an email if I find something interesting about Neurocrine Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Neurocrine Biosciences Inc.

Receive notifications about Neurocrine Biosciences Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.